A FedEx worker walks past his truck in the North Beach neighborhood on June 23, 2026 in San Francisco, California. Heather Diehl | Getty Images As demand rises for specialized medications like GLP-1s, logistics companies including UPS and FedEx are adapting their strategies to be able to better ship and store those pharmaceuticals. Most injectable…
Michael Siluk | UCG | Universal Images Group | Getty Images Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder. Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around obesity treatment drive troves of patients – some studies estimate roughly half…
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift…
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even so, they’re already outlining their visions for the future of obesity drugs. At the American Diabetes Association’s Scientific Sessions in New Orleans last week, drugmakers pitched doctors and investors on the idea of new shots…
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months…
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight. LifeMD went from seeing between 300 and 400 new patients a day to 600 to 1,000 new patients a day, said CEO Justin Schreiber. He knew there…
Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a “bubble effect” as profitability soars, new research suggests. Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is…
When Branneisha Cooper first began taking GLP-1 injection Mounjaro in late 2022, she heard online that she could experience temporary hair thinning and prepared for the worst. But it would take about a year before she began noticing her hair falling out in clumps. Cooper said it was especially shocking because she has always had…
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by $2 billion, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro spiked again. The pharmaceutical giant now expects 2026 revenue to come in between $82 billion and $85 billion, up from…
